Glimzen-MV2 Forte Tablet SR is a combination oral hypoglycemic agent formulated to improve glycemic control in patients with type 2 diabetes mellitus. This extended-release tablet contains Glimepiride 2mg, Metformin 1000mg, and Voglibose 0.2mg, each contributing distinct mechanisms to optimize blood glucose regulation. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, enhancing glucose uptake in muscle tissues. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, attenuating postprandial hyperglycemia. The sustained-release formulation ensures a gradual release of active ingredients, promoting consistent plasma concentrations and improved patient compliance with reduced dosing frequency. Glimzen-MV2 Forte is indicated for patients inadequately controlled on diet and exercise alone or on monotherapy with either sulfonylurea or metformin. It should be used under medical supervision, with regular monitoring of blood glucose levels, renal function, and potential adverse effects such as hypoglycemia, gastrointestinal disturbances, or lactic acidosis. This combination therapy offers a comprehensive approach to managing hyperglycemia by targeting multiple pathophysiological defects in type 2 diabetes.